228 related articles for article (PubMed ID: 31937234)
21. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.
Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ
Front Immunol; 2021; 12():782448. PubMed ID: 34868059
[TBL] [Abstract][Full Text] [Related]
23. Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells.
He Y; Li XM; Yin CH; Wu YM
J Reprod Immunol; 2020 Jun; 139():103115. PubMed ID: 32199196
[TBL] [Abstract][Full Text] [Related]
24. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
[TBL] [Abstract][Full Text] [Related]
25. Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.
Caruso HG; Tanaka R; Liang J; Ling X; Sabbagh A; Henry VK; Collier TL; Heimberger AB
J Neurooncol; 2019 Dec; 145(3):429-439. PubMed ID: 31686330
[TBL] [Abstract][Full Text] [Related]
26. [The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].
Chen Y; Mo ZM; Qin DY; Guo FC; Liao XL; Hu M; Chen Q; Wang YS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 50(2):145-151. PubMed ID: 31106530
[TBL] [Abstract][Full Text] [Related]
27. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
[TBL] [Abstract][Full Text] [Related]
28. Determinants of response and resistance to CAR T cell therapy.
Lesch S; Benmebarek MR; Cadilha BL; Stoiber S; Subklewe M; Endres S; Kobold S
Semin Cancer Biol; 2020 Oct; 65():80-90. PubMed ID: 31705998
[TBL] [Abstract][Full Text] [Related]
29. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
30. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
31. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
33. Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells in Humans.
Liu C; Ayyar VS; Zheng X; Chen W; Zheng S; Mody H; Wang W; Heald D; Singh AP; Cao Y
Clin Pharmacol Ther; 2021 Mar; 109(3):716-727. PubMed ID: 33002189
[TBL] [Abstract][Full Text] [Related]
34.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
35. Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells.
Zhu X; Hu H; Xiao Y; Li Q; Zhong Z; Yang J; Zou P; Cao Y; Meng F; Li W; You Y; Guo AY; Zhu X
Cancer Lett; 2022 Jun; 536():215668. PubMed ID: 35367518
[TBL] [Abstract][Full Text] [Related]
36. Design, Synthesis, and Targeted Delivery of an Immune Stimulant that Selectively Reactivates Exhausted CAR T Cells.
Napoleon JV; Zhang B; Luo Q; Srinivasarao M; Low PS
Angew Chem Int Ed Engl; 2022 Apr; 61(15):e202113341. PubMed ID: 35088497
[TBL] [Abstract][Full Text] [Related]
37. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
Hughes-Parry HE; Cross RS; Jenkins MR
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
[TBL] [Abstract][Full Text] [Related]
38. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
[TBL] [Abstract][Full Text] [Related]
39. Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells.
Huang Y; Si X; Shao M; Teng X; Xiao G; Huang H
J Hematol Oncol; 2022 Mar; 15(1):38. PubMed ID: 35346311
[TBL] [Abstract][Full Text] [Related]
40. A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity.
Zhang H; Li F; Cao J; Wang X; Cheng H; Qi K; Wang G; Xu K; Zheng J; Fu YX; Yang X
Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33504651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]